Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

This publication has 22 references indexed in Scilit:

• Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
  New England Journal of Medicine, 2008
• Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
  Circulation, 2008
• Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease
  Circulation, 2007
• Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
  Circulation, 2006
• The immune response in atherosclerosis: a double-edged sword
  Nature Reviews Immunology, 2006
• Diagnosis and Management of the Metabolic Syndrome
  Circulation, 2005
• Toward Immunomodulatory and Anti-Inflammatory Properties of Statins
  Trends in Cardiovascular Medicine, 2005
• Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
  Circulation, 2004
• European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
  European Heart Journal, 2003